Table 2.
Univariable analysis of PET/CT imaging parameters showing statistical significance and clinical factors for predicting overall survival.
| Variables | p-Value | Hazard Ratio (95% Confidence Interval) |
C-Index | |
|---|---|---|---|---|
| Age (≤65 years vs. >65 years) | 0.020 | 2.26 (1.14–4.48) | 0.632 | |
| Sex (women vs. men) | 0.346 | 0.73 (0.38–1.41) | 0.574 | |
| Clinical TNM stage | Stage I–II vs. stage III | 0.025 | 2.41 (1.12–5.20) | |
| Stage I–II vs. stage IV | <0.001 | 5.07 (2.18–11.78) | 0.690 | |
| Serum CEA (≤5.00 ng/mL vs. >5.00 ng/mL) | 0.002 | 2.93 (1.49–5.74) | 0.663 | |
| CA19-9 (≤103.0 U/mL vs. >103.0 U/mL) | 0.021 | 2.28 (1.13–4.59) | 0.632 | |
| NLR (≤4.17 vs. >4.17) | 0.047 | 2.03 (1.01–4.10) | 0.642 | |
| PLR (≤217.54 vs. >217.54) | 0.068 | 1.85 (0.96–3.57) | 0.625 | |
| Treatment (surgery vs. others treatments) | 0.048 | 1.91 (1.02–3.70) | 0.602 | |
| BM imaging parameters | BM SUV (≤1.53 vs. >1.53) | 0.002 | 4.47 (1.73–11.51) | 0.678 |
| BLR (≤0.79 vs. >0.79) | 0.003 | 4.76 (1.68–13.54) | 0.658 | |
| Conventional PET/CT parameters | Peak SUV (≤6.65 vs. >6.65) | 0.048 | 2.90 (1.01–6.53) | 0.622 |
| MTV (≤15.60 cm3 vs. >15.60 cm3) | 0.021 | 2.18 (1.12–4.21) | 0.619 | |
| TLG (≤41.40 g vs. >41.40 g) | 0.002 | 3.80 (1.65–8.72) | 0.655 | |
| First-order textural parameter | Entropy (≤3.40 vs. >3.40) | 0.002 | 2.87 (1.47–5.61) | 0.650 |
| Higher-order textural parameters | GLCM energy (≤0.012 vs. >0.012) | 0.011 | 0.43 (0.22–0.82) | 0.648 |
| GLCM entropy (≤6.45 vs. >6.45) | 0.027 | 2.10 (1.09–4.05) | 0.640 | |
| GLZLM zone length nonuniformity (≤22.03 vs. >22.03) | 0.035 | 2.03 (1.05–3.91) | 0.640 | |
BM, bone marrow; BLR, bone marrow-to-liver uptake ratio; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; C-index, Harrell’s concordance index; GLCM, grey-level co-occurrence matrix; GLZLM, grey-level zone length matrix; MTV, metabolic tumor volume; NLR, neutrophil-to-lymphocyte ratio; PET/CT, positron emission tomography/computed tomography; PLR, platelet-to-lymphocyte ratio; SUV, standardized uptake value; TLG, total lesion glycolysis.